Contraindications for Eviplera
Additions have been made to the list of mutations that exclude patients with HIV from treatment with Eviplera (emtricitabine/rilpivirine/tenofovir; Gilead). These are the tenofovir resistance-associated substitution K70E, and the combination of L100I+K103N as a rilpivirine resistance-associated substitution.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066076
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com